Cancer Research Institute | Advancing Immunotherapy Research
Cancer Research. The Cancer Research Institute (CRI) is a nonprofit organization dedicated exclusively to advancing immunotherapy to treat,...
Read Cancerresearch.org news digest here: view the latest Cancer Research articles and content updates right away or get to their most visited pages. Cancerresearch.org belongs to a group of fairly successful websites, with more than 60K visitors from all over the world monthly. It seems that Cancer Research content is notably popular in USA, as 44.9% of all users (27K visits per month) come from this country. We haven’t detected security issues or inappropriate content on Cancerresearch.org and thus you can safely use it. Cancerresearch.org is hosted with WPEngine, Inc. (Spain) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
1 997
Visitors daily -
1 997
Pageviews daily -
6
Google PR -
35 335
Alexa rank
Best pages on Cancerresearch.org
-
Cancer Research Institute | Advancing Immunotherapy Research
The Cancer Research Institute (CRI) is a nonprofit organization dedicated exclusively to advancing immunotherapy to treat, control, and cure all cancers.
-
Cancer Research Institute - The Leader in Cancer Immunotherapy - CRI
The Cancer Research Institute was founded in 1953 by Helen Coley Nauts to continue the work begun by her father, Dr. William B. Coley, who pioneered non-surgical, immune-based treatments for cancer.
-
Cancer Research Institute - The Leader in Cancer Immunotherapy - CRI
CRI scientific leaders ensure that our programs continue to achieve the most impact possible and that CRI remains at the cutting-edge of the science of tumor immunology and cancer immunotherapy.
Cancerresearch.org news digest
-
1 year
2022 International Cancer Immunotherapy Conference Highlights from Day 4
The final day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) wrapped up an amazing conference in New York City, the first in-person joint scientific conference since 2018. The past four days demonstrated how far the...
-
1 year
2022 International Cancer Immunotherapy Conference Highlights from Day 3
The third day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) focused on two relatively new frontiers in the cancer field, starting with genetically engineered T cell therapies. The first session touched on a variety...
-
1 year
2022 International Cancer Immunotherapy Conference Highlights from Day 2
The second day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) started off by delving deeper into the myeloid cells highlighted during Day 1 of the conference. In contrast to yesterday’s session that focused on their...
-
1 year
2022 International Cancer Immunotherapy Conference Highlights from Day 1
Back for the first time since the COVID-19 pandemic began, the sixth annual CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) kicked off Thursday, September 28 in New York City with exciting sessions.
The first day of CICON22 focused on two of the most important types of immune cells in the context of cancer immunotherapy: T cells and myeloid cells. While T cells act as the foot soldiers of the immune system that directly target and eliminate tumor...
Domain history
| Web host: | WPEngine, Inc. |
| Registrar: | Public Interest Registry |
| Registrant: | PERFECT PRIVACY, LLC |
| Updated: | March 11, 2024 |
| Expires: | October 30, 2024 |
| Created: | September 18, 2002 |
Whois record
Visitor gender
Male
Female
Safety scores
Trustworthiness
ExcellentChild safety
N/A
